BioCryst Pharma price target lowered to $25 by Citizens on HAE outlook

Investing.comWednesday, November 5, 2025 at 10:43:05 AM
BioCryst Pharma price target lowered to $25 by Citizens on HAE outlook

BioCryst Pharma price target lowered to $25 by Citizens on HAE outlook

Citizens has lowered its price target for BioCryst Pharma to $25, reflecting concerns about the company's outlook on hereditary angioedema (HAE). This adjustment is significant as it indicates potential challenges for BioCryst in meeting market expectations, which could impact investor confidence and the company's future growth prospects.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Dave Inc stock price target raised to $310 from $300 at Citizens
PositiveFinancial Markets
Dave Inc has received a positive boost as Citizens has raised its stock price target from $300 to $310. This adjustment reflects growing confidence in the company's performance and potential for future growth, which is great news for investors looking for promising opportunities in the market.
Hamilton Insurance price target raised to $32 from $31 at Citizens
PositiveFinancial Markets
Hamilton Insurance has seen its price target raised to $32 from $31 by Citizens, indicating a positive outlook for the company. This adjustment reflects confidence in Hamilton's performance and potential growth in the insurance market, which is significant for investors and stakeholders looking for promising opportunities.
Citizens reiterates Market Outperform rating on Abivax stock at $114 target
PositiveFinancial Markets
Citizens has reaffirmed its Market Outperform rating on Abivax stock, setting a target price of $114. This endorsement is significant as it reflects confidence in Abivax's potential for growth and success in the market, which could attract more investors and boost the company's stock performance.
Citizens initiates Kalaris stock with Market Outperform rating, $20 price target
PositiveFinancial Markets
Citizens has initiated coverage on Kalaris with a Market Outperform rating and set a price target of $20. This is significant as it reflects confidence in Kalaris's potential for growth and profitability, which could attract investors looking for promising opportunities in the stock market.
Citizens initiates coverage on EZCORP stock with Market Outperform rating
PositiveFinancial Markets
Citizens has initiated coverage on EZCORP stock, giving it a Market Outperform rating. This is significant as it suggests that Citizens believes EZCORP has strong potential for growth, which could attract more investors and positively impact the stock's performance. Investors often look to analysts' ratings to guide their decisions, and this endorsement could lead to increased interest in EZCORP.